ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Enough Initial Tacrolimus Blood Concentration is Crucial Even with Additional Everolimus in Corticosteroid Early Withdrawal Regimen for Kidney Transplant Recipients

H. Sasaki1, T. Tanabe1, H. Higuchi1, T. Tsujimoto2, H. Harada1

1Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan, 2Pharmacy, Sapporo City General Hospital, Sapporo, Japan

Meeting: 2020 American Transplant Congress

Abstract number: C-003

Keywords: Induction therapy, Kidney transplantation, Pharmacokinetics, Rejection

Session Information

Session Name: Poster Session C: Kidney Immunosuppression: Induction Therapy

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Everolimus (EVR) in combination with low-dose calcineurin inhibitor has been demonstrated in clinical trials to have comparable efficacy in low immunological risk kidney transplant and association with a reduced rate of viral infections and chronic rejection in long-term. For wider use, we have recently considered de novo use of EVR in addition to our corticosteroid early withdrawal (CSEW) regimen and evaluated an optimal use to suppress graft rejection in short period retrospectively.

*Methods: Enrolled recipients were 37 recipients who developed biopsy proven (86%) and clinical acute rejection (14%) that were treated with steroid pulse therapy within 1 year after living ABO compatible kidney transplantation in our hospital (AR group). Control group was 85 recipients who did not exhibit acute rejection clinicopathlogically. The immunosuppressive regimen consists of tacrolimus (TAC), mycophenolate mofetil, EVR and basiliximab as induction mAB. Patient characteristics at transplant, TAC-AUC (Area Under the Curve) and trough level of EVR at 1, 3, 6, 12 months were analyzed.

*Results: There were no statistical differences in HLA-mismatch, age at transplant, donor age and duration of renal replacement therapy, but TAC-AUC at 3 months after transplant was significantly lower in AR group than control group (143±6.4 vs 160±5.2 p=0.048) (Fig. 1) despite no difference in other time points including trough level of EVR. ROC (receiver operating curve characteristics) analysis showed that cut-off value in TAC-AUC at 3M was 174 with AUC 0.67 and 95%CI 0.56-0.79 and P value 0.0048 (Fig. 2). Finally we found that significant difference in the cumulative incidence of AR between recipients with lower TAC-AUC (<174) and higher TAC-AUC (174<) (Fig. 3). However this difference didn’t effect on graft survival during two year after transplant. (97.3% in lower AUC vs 96.7% in higher AUC. p=0.86)

*Conclusions: High TAC-AUC at 3 months could be most important parameter to prevent early graft rejection in combination with EVR as CSEW principal even in good risk kidney transplant recipients.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Sasaki H, Tanabe T, Higuchi H, Tsujimoto T, Harada H. Enough Initial Tacrolimus Blood Concentration is Crucial Even with Additional Everolimus in Corticosteroid Early Withdrawal Regimen for Kidney Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/enough-initial-tacrolimus-blood-concentration-is-crucial-even-with-additional-everolimus-in-corticosteroid-early-withdrawal-regimen-for-kidney-transplant-recipients/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences